Search

Your search keyword '"Caroline Flament"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Caroline Flament" Remove constraint Author: "Caroline Flament"
72 results on '"Caroline Flament"'

Search Results

1. RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies

2. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.

3. Data from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

4. Supplementary Figure from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

5. Supplementary Figure from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

6. Supplementary Data from The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

7. Data from Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

8. Supplementary Figure 3 from Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

9. Supplementary Figure 2 from Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

10. Supplementary Figure 4 from Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

11. Supplementary Figure 6 from Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

12. Supplementary Figure 5 from Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

13. Supplementary Materials and Methods and Figures 1-3 from Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab

14. Supplementary Tables 1 - 3, Figures 1 - 2 from Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors

18. Data from Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

19. Supplementary Figure 1 from Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

20. Supplementary Figure Legend from Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

21. Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

22. The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals

23. The polarity and specificity of SARS-CoV2-specific T lymphocyte responses determine disease susceptibility

24. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

25. Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma

26. T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants

27. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

29. Predictors of responses to immune checkpoint blockade in advanced melanoma

30. Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab

31. Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors

32. Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

33. Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients

34. Ecto-calreticulin in immunogenic chemotherapy

35. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

36. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

37. BCR/ABL Promotes Dendritic Cell–Mediated Natural Killer Cell Activation

38. Malignant effusions and immunogenic tumour-derived exosomes

39. Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering

40. CD48 May serve as an accessory molecule for the activation of a subset of human γ/δ T cells

41. An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae

42. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

43. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

44. Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα

45. Rôle des cellules dendritiques dans l'immunité naturelle

46. Dendritic cells and innate defense against tumor cells

47. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

48. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference

49. Dendritic cell derived-exosomes: biology and clinical implementations

50. The potential of exosomes in immunotherapy of cancer

Catalog

Books, media, physical & digital resources